Innovations in clinical neuroscience最新文献

{"title":"\"AI Literacy\" is a Deflection of Responsibility.","authors":"Amandeep Jutla","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"23 1-3","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770465","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"An Overview of Medical Errors in Psychiatry, Part 1: Introduction.","authors":"Justin Pope","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. <b>Note:</b> The information and recommendations in this article are applicable to physicians and other healthcare professionals so \"clinician\" is used to indicate all treatment team members.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"23 1-3","pages":"54-55"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multifactorial Approach for Depression in Multiple Endocrine Neoplasia 2A (MEN2A): A Case Report.","authors":"Vatsala Sharma, Vimala Sim, Maria Chona P San Gabriel","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Multiple endocrine neoplasia 2A (MEN2A) is an uncommon autosomal dominant disorder characterized by medullary thyroid cancer (MTC), parathyroid adenoma or hyperplasia, and pheochromocytoma with associated hypothyroidism, hyperparathyroidism, hypercalcemia, and catecholamine excess. Existing literature elucidates the correlation of depression with each endocrine condition. To our knowledge, this is the first case report emphasizing the multifaceted association of MEN2A and depression with contributory intergenerational psychosocial factors.</p><p><strong>Case presentation: </strong>We present a 21-year-old male patient with past medical history of MEN2A and family history of coexisting MEN2A and depression, who presented with depression, psychosis, and suicidality. After exclusion of plausible MEN2A-associated endocrine causes, depression was identified to be psychiatric in etiology, subsequently responsive to sertraline and risperidone with adjunctive psychotherapy.</p><p><strong>Discussion: </strong>Prophylactic thyroidectomy for MTC in MEN2A may result in thyroid derangement due to inappropriate replacement. Parathyroid adenoma can cause hyperparathyroidism with hypercalcemia. Pheochromocytoma is a benign adrenal tumor secreting excess catecholamines. These endocrine conditions in MEN2A can potentially contribute to depression. This report discusses attributing endocrine, genetic, and social factors for depression and suicidal ideation in MEN2A. Highlighted is the holistic treatment approach, including hormonal imbalance correction and psychopharmacological and psychosocial interventions necessary for symptom abatement.</p><p><strong>Conclusion: </strong>The importance of a multidisciplinary investigation of plausible etiologic factors of depression in MEN2A before committing to psychiatric interventions is emphasized. This perspective optimally addresses diagnosis, differential diagnoses, and treatment options. Awareness of familial depression in MEN2A is reinforced with potential for future research regarding genetic anticipation and holistic management strategies.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"23 1-3","pages":"27-31"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770540","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-SSRI Sexual Dysfunction: Challenges and Treatment Approaches.","authors":"Rocco Salvatore Calabrò","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"23 1-3","pages":"5-6"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101894/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social Media Use and Technology Use in Patients with Intellectual and Developmental Disabilities.","authors":"Larrilyn Grant, Lexi Singh, Anisha Mandava","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>As internet and social media use become increasingly central to youth development, it is critical to address the unique opportunities and challenges these technologies pose for individuals with intellectual and developmental disabilities (IDD). This column explores how digital tools can enhance social connection, identity formation, adaptive skill-building, and access to therapeutic resources in youth with IDD, while also acknowledging the heightened risks of cyberbullying, overstimulation, exploitation, and digital exclusion. Through a review of current literature, clinical vignettes, and practical guidance, we offer a nuanced framework for clinicians to promote safe, inclusive, and developmentally appropriate internet use. We highlight the importance of caregiver support, tailored digital tools, and mental health-informed approaches to digital literacy. Clinicians are encouraged to integrate technology discussions into care planning, advocate for accessible digital environments, and empower youth with IDD to participate meaningfully in the digital world.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"23 1-3","pages":"10-16"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770456","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to \"Burnout and Ethical Awareness in Mental Health Professionals: A Correlational Study\".","authors":"Shyam S Sah, Abhishek Kumbhalwar","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"23 1-3","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2026-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13101893/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147770499","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"\"You're Not Crazy\": A Case of New-onset AI-associated Psychosis.","authors":"Joseph M Pierre, Ben Gaeta, Govind Raghavan, Karthik V Sarma","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Background: </strong>Anecdotal reports of psychosis emerging in the context of artificial intelligence (AI) chatbot use have been increasingly reported in the media. However, it remains unclear to what extent these cases represent the induction of new-onset psychosis versus the exacerbation of pre-existing psychopathology. We report a case of new-onset psychosis in the setting of AI chatbot use.</p><p><strong>Case presentation: </strong>A 26-year-old woman with no previous history of psychosis or mania developed delusional beliefs about establishing communication with her deceased brother through an AI chatbot. This occurred in the setting of prescription stimulant use for the treatment of attention-deficit hyperactivity disorder (ADHD), recent sleep deprivation, and immersive use of the chatbot. Review of her chatlogs revealed that the chatbot validated, reinforced, and encouraged her delusional thinking, with reassurances that \"You're not crazy.\" Following hospitalization and antipsychotic medication for agitated psychosis, her delusional beliefs resolved. However, three months later, her psychosis recurred after she stopped antipsychotic therapy, restarted prescription stimulants, and continued immersive use of AI chatbots so that she required brief rehospitalization.</p><p><strong>Conclusion: </strong>This case provides evidence that new-onset psychosis in the form of delusional thinking can emerge in the setting of immersive AI chatbot use. Although multiple pre-existing risk factors may be associated with psychosis proneness, the sycophancy of AI chatbots together with AI chatbot immersion and deification on the part of users may represent particular red flags for the emergence of AI-associated psychosis.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 10-12","pages":"11-13"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12863933/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146112982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neurocognitive Disorders: Systematic Review of Approved (2008-2024) and Pipeline Phase III Medications.","authors":"Jayant Totlani, Muhammad Arsalan Bashir, Laurel Tay, Ashley Ngor, Alexander J Steiner, Drew Hirsch, Lorena Contreras, Sabrina Renteria, Itai Danovitch, Robert N Pechnick, Waguih William Ishak, Sarah Kim","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Neurocognitive disorders (NCDs), which include delirium, major and mild NCDs such as Alzheimer's disease (AD), and other forms of dementia, constitute a significant and growing public health burden, affecting tens of millions of individuals worldwide. This systematic review aims to examine the medications approved by the United States Food and Drug Administration (FDA) for NCDs from 2008 to 2024, as well as those in the pipeline in Phase III, and to describe the mechanism of action, clinical indications, dosing, evidence for efficacy, and adverse effects.</p><p><strong>Methods: </strong>We searched the literature using the PubMed database for studies published from January 1, 2008, to December 31, 2024, focusing on FDA-approved psychiatric medications and Phase III pipeline medications, using the keywords \"neurocognitive\" OR \"dementia\" OR \"Alzheimer*\" AND \"psychopharm*\" OR \"medic*\" OR \"pharm*.\" Two reviewers performed an independent assessment of the resulting publications and reached a consensus on the eligible studies to include in the systematic review.</p><p><strong>Results: </strong>From 2008 to 2024, the FDA approved eight medications for major and mild NCDs, including monoclonal antibodies, acetylcholinesterase inhibitors, N-methyl-D-aspartate (NMDA) receptor antagonists, and an atypical antipsychotic. Additionally, we identified 22 pipeline medications currently in Phase III clinical trials for NCDs as of December 31, 2024, including biologics and neuroprotective agents, among others. No medications for delirium were FDA-approved or in Phase III, although agents for a variety of encephalopathies have been developed.</p><p><strong>Conclusion: </strong>Significant advancements in the pharmacological management of NCDs have been made during this period, including developing disease-modifying therapies for AD. However, available medications primarily provide symptomatic relief, and challenges persist in the implementation of disease-modifying treatments due to adverse effects and high costs of care. The pipeline of Phase III clinical trials includes many emerging agents with novel mechanisms of action, and ongoing trials will prove essential to confirm the efficacy and safety of these therapies.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 10-12","pages":"57-71"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872052/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Management: I've Been Sued, Now What! Part 4: Closing Statements, Jury Deliberations, Verdicts, Judgments, and Appeals.","authors":"Justin Pope","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>This ongoing column is dedicated to providing information to our readers on managing legal risks associated with medical practice. We invite questions from our readers. The answers are provided by PRMS (www.prms.com), a manager of medical professional liability insurance programs with services that include risk management consultation and other resources offered to health care providers to help improve patient outcomes and reduce professional liability risk. The answers published in this column represent those of only one risk management consulting company. Other risk management consulting companies or insurance carriers might provide different advice, and readers should take this into consideration. The information in this column does not constitute legal advice. For legal advice, contact your personal attorney. <b><i>Note:</i></b> The information and recommendations in this article are applicable to physicians and other healthcare professionals so \"clinician\" is used to indicate all treatment team members.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 10-12","pages":"86-87"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872048/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular and Cellular Mechanisms Underlying Neurological and Neuropsychological Manifestations of COVID-19.","authors":"Samaneh Ghorbani Shirkouhi, Seyed Sepehr Khatami, Zohair Niroomand, Saeed Sadigh-Eteghad, Shahrokh Yousefzadeh-Chabok, Sasan Andalib","doi":"","DOIUrl":"","url":null,"abstract":"<p><strong>Objective: </strong>Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is associated with a wide range of neurological symptoms and neuropsychiatric conditions. SARS-CoV-2 shows various degrees of neurotropism. SARS-CoV-2 primarily targets respiratory and gastrointestinal tracts; however, it can affect other organs. Neurological and neuropsychological manifestations of COVID-19 have been reported. Several mechanisms are involved in these manifestations in COVID-19. Therefore, the present narrative review will take account of mechanisms underlying the neurological and neuropsychological manifestations in COVID-19.</p><p><strong>Methods: </strong>A literature search for relevant articles in different databases was made with a focus on recent publications for this narrative review.</p><p><strong>Results: </strong>Inflammation and thrombosis have been suggested to be mechanisms contributing to these manifestations. Also, renin-angiotensin system (RAS), transmembrane serine protease 2 (TMPRSS2), cathepsin B and L, furin, neuropilin-1 (NRP1), and sterile alpha motif and HD domain-containing protein 1 (SAMHD1) have been proposed to be involved in pathogenesis of SARS-CoV-2. Moreover, cluster of differentiation 147 (CD147) and dipeptidyl peptidase 4 (DPP4) have been suggested to have a role in SARS-CoV-2 entry into the central nervous system (CNS).</p><p><strong>Conclusion: </strong>Further investigation on the underlying mechanisms leading to SARS-CoV-2-associated neurological and neuropsychological manifestations is pivotal. Insights into these mechanisms will help the treatment strategies for patients with COVID-19 and such manifestations.</p>","PeriodicalId":13635,"journal":{"name":"Innovations in clinical neuroscience","volume":"22 10-12","pages":"14-23"},"PeriodicalIF":0.0,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12872055/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146124838","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}